Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NAFLD rat models were established and treated with BP and SIRT1 siRNA.
|
30785444 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SIRT1 gene rs33957861 and rs11599176 polymorphisms significantly reduce the risk of NAFLD and AFLD, while rs35689145 remarkably increases the risk.
|
29189974 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we summarize the latest advances of the biological roles of SIRT1 in regulating lipid metabolism, oxidative stress and inflammation in the liver, and discuss the potential of SIRT1 as a therapeutic target for treating alcoholic and nonalcoholic fatty liver diseases.
|
28808418 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of the inhibitory effects of γ-mangostin on lipid accumulation revealed that it downregulated NAFLD-related biochemical parameters and stimulated the SIRT1/LKB1/AMPK pathway.
|
31674780 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sirtuin 1 (Sirt1) is suppressed in non-alcoholic fatty liver disease (NAFLD), while its' stimulation or overexpression results in reduced disease severity in pre-clinical NAFLD models.
|
29696666 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Palmitic acid-induced muscle cell dysfunction occurs, at least in part, through activation of the miR-34a/SIRT1:AMPK pathway. miR-34a/SIRT1:AMPK activation associates with mitochondria dynamics dysfunction in human NAFLD.
|
31139863 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sirtuin 1 (SIRT1) is an NAD(+)‑dependent deacetylase, and a critical regulator in various metabolic processes, such as non‑alcoholic fatty liver disease (NAFLD).
|
29845302 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial.
|
30263038 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aims to determine the effects of green cardamom (Elettaria cardamomum) supplementation on blood glucose indices, lipids, inflammatory profiles, and liver function, especially by examining irisin, paraxonase-1 (PON1) and sirtuin-1 (Sirt1) in obese patients with NAFLD.
|
28592311 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease <i>via</i> the Sirt1/AMPK and NF-κB signaling pathways.
|
31558861 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Downregulation of miR-34a may be a therapeutic strategy against NAFLD by regulating its target PPARα and SIRT1.
|
26330104 |
2015 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
miR-34a, apoptosis and acetylated p53 increased with disease severity, while SIRT1 diminished in the NAFLD liver.
|
22902550 |
2013 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, autophagy is induced by the SIRT1-FoxO signaling pathway and was recently shown to be a critical protective mechanism against non-alcoholic fatty liver disease (NAFLD) development.
|
28817690 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, our findings further demonstrated that dioscin markedly prevented NAFLD through adjusting lipid metabolism via SIRT1/AMPK signal pathway, which should be developed as a new candidate for NAFLD.
|
29574225 |
2018 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the role of SIRT1-mediated inhibition of HMGB1 release in NAFLD and the effect of salvianolic acid B (SalB), which is a water-soluble phenolic acid extracted from Radix Salvia miltiorrhiza, on NAFLD through SIRT1/HMGB1 signaling.
|
26525891 |
2015 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we identified 2 miR-9 targets, Onecut2 and SIRT1, which may be crucial players in NAFLD development.
|
27756894 |
2016 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The inhibition of miR-122 protects hepatocytes from lipid metabolic disorders such as NAFLD and suppresses lipogenesis via elevating Sirt1 and activating the AMPK pathway.
|
31195981 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, inhibition of phosphorylation of SIRT1 by CK2 may serve as a new therapeutic approach for treatment of NAFLD and other obesity-related diseases.
|
28533219 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sirtuin1 (SIRT1), which is regulated by microRNA-34a (miR-34a), can modulate pathophysiology processes, including nonalcoholic fatty liver disease and intestinal ischemia/reperfusion injury.
|
31296380 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our data suggest that nicotinamide protects against palmitate-induced hepatotoxicity via SIRT1-dependent autophagy induction and that nicotinamide supplementation may represent a therapeutic choice for NAFLD.
|
28473059 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusions Resveratrol is a promising agent for the treatment of hyperuricemia-related NAFLD through activating SIRT1 pathways.
|
30557833 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The impact of uric acids on liver pathology, and the expression patterns of key molecules involved in the development of NAFLD, including silent information regulator 1 (SIRT1), nuclear factor kappa B subunit p65 (NF-κB p65), fork-head box class O-3a (FOXO3a), androgen receptor (AR), and xanthine oxidase (XO) were analysed.
|
31252266 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results indicated that GGQLD treatment may be a potent strategy for managing NAFLD by managing lipid metabolism and inflammatory and histological abnormalities by triggering the Sirt1 pathway.
|
29104641 |
2017 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Micro-RNA-34a-5p, a direct inhibitor of SIRT1, is an emerging indicator of NAFLD grading.
|
31500354 |
2019 |
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies suggest that SIRT1, a NAD(+)-dependent deacetylase, protects rats from NAFLD.
|
20033348 |
2010 |